The DOI matches its Crossref record; 227 of the 227 references it cites were found in a registry or an index.
Gastroenteropancreatic Neuroendocrine Tumors
Open accessAbstract
Neuroendocrine tumors (NETs) are heterogeneous malignancies arising from the diffuse neuroendocrine system. They frequently originate in the gastroenteropancreatic (GEP) tract and the bronchopulmonary tree, and their incidence has steadily increased in the last 3 decades. Fundamental biologic and genomic differences underlie the clinical heterogeneity of NETs, and distinct molecular features characterize NETs of different grades and different primary sites. Although surgery remains the cornerstone of treatment for localized tumors, systemic treatment options for patients with metastatic NETs have expanded considerably. Somatostatin analogs have demonstrated both antisecretory and antitumor efficacy. Peptide receptor radionuclide therapy with lutetium‐177 dotatate ( 177 Lu‐DOTATATE) has been approved for advanced GEP‐NETs. The antitumor activity of everolimus has been demonstrated across a wide spectrum of NETs, and the antiangiogenic agent sunitinib has been approved for pancreatic NETs (pNETs). Chemotherapy with temozolomide and capecitabine has recently demonstrated an unprecedented prolongation of progression‐free survival in a randomized trial of pNETs. Multiple retrospective series have reported the efficacy of liver‐directed therapies both for palliating symptoms of hormone excess and for controlling tumor growth. Telotristat, an oral inhibitor of tryptophan hydroxylase, has been shown to reduce diarrhea in patients with carcinoid syndrome. Defining the therapeutic algorithm and identifying biomarkers predictive of response to treatments are among the main priorities for the next decade of research in the NET field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–227 of 227
Saund, M. S., Al Natour, R. H., Sharma, A. M., Huang, Q., Boosalis, V. A., & Gold, J. S. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1652-0 · Cited by 67
Grozinsky‐Glasberg, S., Alexandraki, K., Barak, D. F., et al. (2012) · Neuroendocrinology · doi:10.1159/000343801 · Cited by 67
Kahil, M. E. (1964) · Archives of Internal Medicine · doi:10.1001/archinte.1964.03860070072004 · Cited by 58
Use of octreotide acetate for control of symptoms in patients with islet cell tumors
Maton, P. N. (1993) · World Journal of Surgery · doi:10.1007/bf01655110 · Cited by 57
Modlin, I. M. (1995) · Archives of Surgery · doi:10.1001/archsurg.1995.01430030020003 · Cited by 57
Necrolytic migratory erythema and zinc deficiency
Sinclair, S. A., & Reynolds, N. J. (1997) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1997.6761623.x · Cited by 54
An update on gastroenteropancreatic neuroendocrine tumors.
Cives, M., & Strosberg, J. (2014) · PubMed · Cited by 53
Self-citationCarcinoid heart disease: Diagnosis and management
Luis, S. A., & Pellikka, P. A. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.09.005 · Cited by 53
Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome
Gibril, F., & Jensen, R. T. (2005) · Current Gastroenterology Reports · doi:10.1007/s11894-005-0049-2 · Cited by 53
Frequency and Clinical Correlates of Somatic Ying Yang 1 Mutations in Sporadic Insulinomas
Lichtenauer, U. D., Dalmazi, G. D., Slater, E. P., Wieland, T., Kuebart, A., Schmittfull, A., Schwarzmayr, T., Diener, S., Wiese, D., Thasler, W. E., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1100 · Cited by 51
The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors
Cives, M., & Strosberg, J. (2015) · Drugs · doi:10.1007/s40265-015-0397-7 · Cited by 50
Self-citationWoltering, E. A., Mamikunian, P., Zietz, S., Krutzik, S. R., Go, V. L. W., Vinik, A. I., Vinik, E. J., O’Dorisio, T. M., & Mamikunian, G. (2005) · Pancreas · doi:10.1097/01.mpa.0000186249.89081.0d · Cited by 48
Tachykinins in endocrine tumors and the carcinoid syndrome
Cunningham, J. L., Janson, E. T., Agarwal, S., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0196 · Cited by 47
Rinzivillo, M., Partelli, S., Prosperi, D., Capurso, G., Pizzichini, P., Iannicelli, E., Merola, E., Muffatti, F., Scopinaro, F., Schillaci, O., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0278 · Cited by 45
Desai, D. C., O’Dorisio, T. M., Schirmer, W. J., Jung, S. S., Khabiri, H., Villanueva, V., & Martin, E. W. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00167-1 · Cited by 40
Merola, E., Pavel, M. E., Panzuto, F., Capurso, G., Cicchese, N., Rinke, A., Gress, T. M., Iannicelli, E., Prosperi, D., Pizzichini, P., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3732 · Cited by 35
Hughes, M. S., Azoury, S. C., Assadipour, Y., Straughan, D. M., Trivedi, A. N., Lim, R. M., Joy, G., Voellinger, M. T., Tang, D. M., Venkatesan, A. M., et al. (2015) · Surgery · doi:10.1016/j.surg.2015.05.041 · Cited by 34
Okamoto, Y., Fujii, M., Tateiwa, S., Sakai, T., Ochi, F., Sugano, M., Oshiro, K., Masai, K., & Okabayashi, Y. (2004) · Endoscopy · doi:10.1055/s-2004-814386 · Cited by 31
Degg, T. J., Allen, K. R., & Barth, J. H. (2000) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/0004563001899780 · Cited by 30
Nonfunctioning Incidental Pancreatic Neuroendocrine Tumors
Gorelik, M., Ahmad, M. S., Grossman, D., Grossman, M. B., & Cooperman, A. M. (2017) · Surgical Clinics of North America · doi:10.1016/j.suc.2017.09.014 · Cited by 26
Carcinoid tumours of the appendix are different
Shaw, P. A. (1990) · The Journal of Pathology · doi:10.1002/path.1711620303 · Cited by 25
Islet cell tumors of the pancreas.
Whipple, A. O. (1952) · PubMed Central · Cited by 23
Moses, R., Frank, B. B., Leavitt, M., et al. (1986) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-198602000-00013 · Cited by 22
Rogers, A., Wang, L. M., Karavitaki, N., et al. (2012) · QJM · doi:10.1093/qjmed/hcs203 · Cited by 18
van der Horst‐Schrivers, A. N. A., Wymenga, A. N. M., & de Vries, E. G. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmc030888 · Cited by 14
Overexpression of glut-1 glucose transporter in human breast cancer an immunohistochemical study
(1993) · doi:10.1002/1097-0142(19931115)72:10 · Cited by 1
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Cited by
Strosberg, J. R., Caplin, M. E., Kunz, P. L., Ruszniewski, P. B., Bodei, L., Hendifar, A., Mittra, E., Wolin, E. M., Yao, J. C., Pavel, M. E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00572-6 · Cited by 578
Self-citationCurrent advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Grossberg, A. J., Chu, L. C., Deig, C. R., Fishman, E. K., Hwang, W. L., Maitra, A., Marks, D. L., Mehta, A., Nabavizadeh, N., Simeone, D. M., et al. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21626 · Cited by 489
Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
Das, S., & Dasari, A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01029-7 · Cited by 391
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
Metadata
- Authors
- Cives, M., & Strosberg, J. R.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2018-10-08
- Volume
- 68
- Issue
- 6
- Pages
- 471-487
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W2896748530
- Cited by
- 586
- References
- 227
- FWCI
- 32.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.